Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | CYSLTR2 | Q9NS75 | 6/20 | 0.36 |
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | PIP5K1A | Q99755 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454649 | 0.86 | GAA (0.46) | GAACSNK2BCSNK2A1CYP1A1PIP5K1A | |
| SCHEMBL3896297 | 0.86 | CSNK2B (0.41) | GAACSNK2BCSNK2A1CYP1A1NR1H2 | |
| SCHEMBL3897037 | 0.86 | CSNK2B (0.41) | GAACSNK2BCSNK2A1CYP1A1NR1H2 | |
| SCHEMBL4449574 | 0.81 | GAA (0.42) | GAACSNK2BCSNK2A1CYP1A1NR1H2 | |
| Nonane SCHEMBL27663344 | 0.74 | GAA (0.56) | GAA | |
| SCHEMBL2229814 | 0.74 | KMT2A (0.49) | CYSLTR2CYSLTR1 | |
| SCHEMBL3896295 | 0.71 | CYSLTR2 (0.47) | CYP1A1NR1H2NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL11708641 | 0.69 | ELANE (0.45) | CYP1A1NR1H2NR1H3LIPGTYR | |
| SCHEMBL1557118 | 0.68 | GAA (0.33) | GAACSNK2BCSNK2A1CYP1A1 | |
| SCHEMBL323496 | 0.68 | ESR1 (0.37) | CSNK2BCSNK2A1CYP1A1PIP5K1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6224791-B1 | PHENYLBENZOFURAN-2-ONE WITH PHOSPHITE | DOVER CHEMICAL CORPORATION | 2001-05-01 | — | — | US | claimed |
| WO-1999003915-A1 | LACTONE/PHOSPHITE BLENDS | DOVER CHEMICAL CORPORATION (US) | 1999-01-28 | — | — | WO | claimed |
| EP-1692150-A4 | PROCESS FOR MANUFACTURE OF PENTAERYTHRITOL DIPHOSPHITES | DOVER CHEMICAL CORP (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7470735-B2 | Phenol-free phosphites | DOVER CHEMICAL CORPORATION (US) | 2008-12-30 | — | — | US | disclosed |
| US-7342060-B2 | Process for manufacture of pentaerythritol diphosphites | DOVER CHEMICAL CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1692150-A2 | PROCESS FOR MANUFACTURE OF PENTAERYTHRITOL DIPHOSPHITES | Dover Chemical Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005113665-A2 | PHENOL-FREE PHOSPHITES | DOVER CHEMICAL CORPORATION (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005060500-A2 | PROCESS FOR MANUFACTURE OF PENTAERYTHRITOL DIPHOSPHITES | DOVER CHEMICAL CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050131244-A1 | PROCESS FOR MANUFACTURE OF PENTAERYTHRITOL DIPHOSPHITES | DOVER CHEMICAL CORPORATION (US) | 2005-06-16 | — | — | US | disclosed |
| US-20040180999-A1 | PHENOL-FREE PHOSPHITES | DOVER CHEMICAL CORPORATION (US) | 2004-09-16 | — | — | US | disclosed |
| US-6770693-B2 | COMPRISING BIS-(2,4-DICUMYLPHENYL) PENTAERYTHRITOL DIPHOSPHITE AND HINDERED PHENOL ANTIOXIDANTS USEFUL AS STABILIZERS AGAINST THERMOOXIDATIVE DEGRADATION OF POLYMERS DURING MELT PROCESSING | DOVE CHEMICAL CORPORATION | 2004-08-03 | — | — | US | disclosed |
| US-20020040081-A1 | Blends of phosphites and antioxidants | DOVER CHEMICAL | 2002-04-04 | — | — | US | disclosed |
| US-6224791-B1 | PHENYLBENZOFURAN-2-ONE WITH PHOSPHITE | DOVER CHEMICAL CORPORATION | 2001-05-01 | — | — | US | disclosed |
| WO-1999003915-A1 | LACTONE/PHOSPHITE BLENDS | DOVER CHEMICAL CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131244-A1 | PROCESS FOR MANUFACTURE OF PENTAERYTHRITOL DIPHOSPHITES | GNPAT, DCTPP1, DERA | GAA 2344/4885CSNK2B 3158/4885CSNK2A1 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.